Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-13 |
2024-03 |
-2.01 |
-2.84 |
-0.83 |
-41.29% |
2024-03-05 |
2023-12 |
-3.15 |
-2.97 |
0.18 |
5.71% |
2024-03-05 |
2023-12 |
-3.15 |
N/A |
N/A |
N/A |
2023-11-07 |
2023-09 |
-5.25 |
-2.7 |
2.55 |
48.57% |
2023-11-07 |
2023-09 |
-5.25 |
N/A |
N/A |
N/A |
2023-08-09 |
2023-06 |
-9.9 |
-7.35 |
2.55 |
25.76% |
Date |
Firm |
Action |
From |
To |
2023-10-02 |
Wedbush |
Upgrade |
Neutral |
Neutral |
2023-09-18 |
Truist Securities |
Upgrade |
|
Buy |
2023-08-09 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-08 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-06-19 |
Wedbush |
Upgrade |
Neutral |
Neutral |
2023-06-11 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2021-10-05 |
BSOF PARALLEL MASTER FUND L.P. |
Beneficial Owner of more than 10% of a Class of Security |
0.00 |
Sale |
2023-10-04 |
DESIMONE JILL |
Director |
14.50K |
Purchase |
2023-05-11 |
KELLY TIMOTHY EDWIN |
Chief Financial Officer |
58.10K |
Stock Award(Grant) |
2022-06-15 |
MASTROCOLA LAUREN |
Officer |
31.39K |
Purchase |
2023-03-23 |
MITCHELL DEAN J |
Director |
75.00K |
Purchase |
2023-05-11 |
NEMIROFF ALEX |
General Counsel |
49.46K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Point72 Asset Management, L.P. |
10.55M |
12.13M |
8.21% |
2023-06-29 |
Verition Fund Management, LLC |
10.49M |
12.06M |
8.16% |
2023-06-29 |
Cormorant Asset Management, LP |
9.50M |
10.93M |
7.39% |
2023-06-29 |
Pfm Health Sciences, Lp |
8.89M |
10.23M |
6.92% |
2023-06-29 |
Sphera Funds Management Ltd. |
8.76M |
10.08M |
6.82% |
2023-06-29 |
Adage Capital Partners GP L.L.C. |
7.93M |
9.12M |
6.17% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.67M |
1.92M |
1.30% |
2023-06-29 |
Vanguard Extended Market Index Fund |
576.83K |
663.36K |
0.45% |
2023-07-30 |
Federated Hermes MDT Mid Cap Growth Fund |
360.56K |
356.99K |
0.28% |
2023-05-30 |
Fidelity Extended Market Index Fund |
208.00K |
178.84K |
0.16% |
2023-05-30 |
Vanguard Russell 2000 Index Fund |
128.08K |
110.12K |
0.10% |
2023-08-30 |
iShares Micro Cap ETF |
119.87K |
176.21K |
0.09% |
Split |
Date |
1 : 15 |
2023-11-29 |